Mather Group’s Viking Therapeutics VKTX Stock Holding History

Mather Group’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3	Closed	-$79	–	1613
2025 Q3	$79	Buy	+3	New	+$89	﹤0.01%	1689

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Mather Group's VKTX Position: Q4 2025 in Review

Mather Group sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 3 shares — an estimated $79 sold.

Mather Group first reported a position in VKTX in Q3 2025 and held it in 1 quarter. The position peaked at $79 in Q3 2025. 427 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

Mather Group reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
Mather Group sold 3 Viking Therapeutics shares in Q4 2025, an estimated $79.
Mather Group first reported a position in Viking Therapeutics in Q3 2025 and held it in 1 quarter.
Mather Group's Viking Therapeutics position peaked at $79 in Q3 2025.
427 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on Mather Group's 13F filing for Q4 2025, filed 13 Jan 2026.